Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy

Table 2

PSA dynamics.

Patient #	Age at initial treatment; (yrs)	Time between 1st and 2nd Brachytherapy; (mo)	Pre-salvage PSA; (ng/mL)	Presalvage PSA; (ng/dL)	Follow-up; (mo)	Time to nadir; (mo)
1	57	38	6.3	3.6	149	21
2	61	32	5.3	3.6	132	31
3	65	26	4.5	4.4	86	73
4	63	34	10	2.5	111	6
5	59	26	4.9	2.7	119	10
6	50	67	8	14.9	83	10
7	48	287	x	8.6	34	22
8	60	123	7.2	17.41	10	9
9	55	120	6.3	1.53	67	7
10	57	19	5.3	3.49	49	48
11	48	25	6.93	2.77	41	41
12	66	4	4.7	1.86	15	4
13	44	31	8.7	2.41	41	29
14	50	87	7.4	7.3	39	33
15	66	42	19.1	1.68	52	9
16	71	45	6.4	3.11	40	5
17	63	48	8.2	13.8	49	3
18	42	50	1	0.98	40	41
19	58	105	x	11.58	52	17
20	59	48	5.7	4.24	25	7
21	72	21	5.8	3.1	21	15
Mean	57.8	62.9	6.9	5.5	61.4	20.9
Median	59.0	45.0	6.3	3.5	49.0	15.0
SD	8.4	60.2	3.5	4.9	37.9	18.3
	21	21	19	21	21	21

x = data point not known.